{"id":33674,"date":"2025-05-19T17:28:21","date_gmt":"2025-05-19T09:28:21","guid":{"rendered":"https:\/\/flcube.com\/?p=33674"},"modified":"2025-05-19T17:28:21","modified_gmt":"2025-05-19T09:28:21","slug":"novo-nordisk-ceo-lars-fruergaard-jorgensen-to-step-down-amid-market-challenges","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33674","title":{"rendered":"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges"},"content":{"rendered":"\n

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO<\/a>, CPH: NOVO-B<\/a>) announced last week that Lars Fruergaard J\u00f8rgensen, its current President and CEO, will step down from the chief executive role. J\u00f8rgensen will remain in his position temporarily to ensure a smooth leadership transition. This executive shift follows recent market challenges and stock price volatility faced by the company. Concurrently, Lars Rebien S\u00f8rensen, Chairman of the Novo Nordisk Foundation, will join the company’s board as an observer and is expected to be nominated for board membership at the 2026 Annual General Meeting.<\/p>\n\n\n\n

J\u00f8rgensen’s Tenure and Achievements<\/strong>
Since assuming the role of President and CEO in 2017, J\u00f8rgensen has been instrumental in driving significant growth in sales, profits, and market capitalization. Under his leadership, Novo Nordisk solidified its position as a global leader in diabetes and obesity therapies.<\/p>\n\n\n\n

Future Outlook and Governance Changes<\/strong>
The transition in leadership comes at a time when the company is navigating market challenges. The addition of Lars Rebien S\u00f8rensen to the board as an observer, with an expected nomination for board membership in 2026, underscores the company’s commitment to maintaining strong governance and strategic direction.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard…<\/p>\n","protected":false},"author":1,"featured_media":33675,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[1250,860],"class_list":["post-33674","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-cph-novo-b","tag-nyse-nvo"],"yoast_head":"\nNovo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard J\u00f8rgensen, its current President and CEO, will step down from the chief executive role. J\u00f8rgensen will remain in his position temporarily to ensure a smooth leadership transition. This executive shift follows recent market challenges and stock price volatility faced by the company. Concurrently, Lars Rebien S\u00f8rensen, Chairman of the Novo Nordisk Foundation, will join the company's board as an observer and is expected to be nominated for board membership at the 2026 Annual General Meeting.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33674\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges\" \/>\n<meta property=\"og:description\" content=\"Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard J\u00f8rgensen, its current President and CEO, will step down from the chief executive role. J\u00f8rgensen will remain in his position temporarily to ensure a smooth leadership transition. This executive shift follows recent market challenges and stock price volatility faced by the company. Concurrently, Lars Rebien S\u00f8rensen, Chairman of the Novo Nordisk Foundation, will join the company's board as an observer and is expected to be nominated for board membership at the 2026 Annual General Meeting.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33674\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-19T09:28:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1904.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges\",\"datePublished\":\"2025-05-19T09:28:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674\"},\"wordCount\":210,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1904.webp\",\"keywords\":[\"CPH: NOVO-B\",\"NYSE: NVO\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33674#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33674\",\"name\":\"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1904.webp\",\"datePublished\":\"2025-05-19T09:28:21+00:00\",\"description\":\"Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard J\u00f8rgensen, its current President and CEO, will step down from the chief executive role. J\u00f8rgensen will remain in his position temporarily to ensure a smooth leadership transition. This executive shift follows recent market challenges and stock price volatility faced by the company. Concurrently, Lars Rebien S\u00f8rensen, Chairman of the Novo Nordisk Foundation, will join the company's board as an observer and is expected to be nominated for board membership at the 2026 Annual General Meeting.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33674\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1904.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1904.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33674#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges - Insight, China's Pharmaceutical Industry","description":"Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard J\u00f8rgensen, its current President and CEO, will step down from the chief executive role. J\u00f8rgensen will remain in his position temporarily to ensure a smooth leadership transition. This executive shift follows recent market challenges and stock price volatility faced by the company. Concurrently, Lars Rebien S\u00f8rensen, Chairman of the Novo Nordisk Foundation, will join the company's board as an observer and is expected to be nominated for board membership at the 2026 Annual General Meeting.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33674","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges","og_description":"Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard J\u00f8rgensen, its current President and CEO, will step down from the chief executive role. J\u00f8rgensen will remain in his position temporarily to ensure a smooth leadership transition. This executive shift follows recent market challenges and stock price volatility faced by the company. Concurrently, Lars Rebien S\u00f8rensen, Chairman of the Novo Nordisk Foundation, will join the company's board as an observer and is expected to be nominated for board membership at the 2026 Annual General Meeting.","og_url":"https:\/\/flcube.com\/?p=33674","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-19T09:28:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1904.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33674#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33674"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges","datePublished":"2025-05-19T09:28:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33674"},"wordCount":210,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33674#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1904.webp","keywords":["CPH: NOVO-B","NYSE: NVO"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33674#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33674","url":"https:\/\/flcube.com\/?p=33674","name":"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33674#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33674#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1904.webp","datePublished":"2025-05-19T09:28:21+00:00","description":"Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard J\u00f8rgensen, its current President and CEO, will step down from the chief executive role. J\u00f8rgensen will remain in his position temporarily to ensure a smooth leadership transition. This executive shift follows recent market challenges and stock price volatility faced by the company. Concurrently, Lars Rebien S\u00f8rensen, Chairman of the Novo Nordisk Foundation, will join the company's board as an observer and is expected to be nominated for board membership at the 2026 Annual General Meeting.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33674#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33674"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33674#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1904.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1904.webp","width":1080,"height":608,"caption":"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33674#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen to Step Down Amid Market Challenges"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1904.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33674"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33674\/revisions"}],"predecessor-version":[{"id":33676,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33674\/revisions\/33676"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33675"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}